Similar articles

• The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

  Racke MK, Lovett-Racke AE, Karandikar NJ. Racke MK, et al. Neurology. 2010 Jan 5;74 Suppl 1:S25-30. doi: 10.1212/WNL.0b013e3181c97e39. Neurology. 2010. PMID: 20038760 Review.
• Mitoxantrone and cytotoxic drugs' mechanisms of action.

  Vollmer T, Stewart T, Baxter N. Vollmer T, et al. Neurology. 2010 Jan 5;74 Suppl 1:S41-6. doi: 10.1212/WNL.0b013e3181c97f5a. Neurology. 2010. PMID: 20038762
• Monoclonal antibodies in MS: mechanisms of action.

  Bielekova B, Becker BL. Bielekova B, et al. Neurology. 2010 Jan 5;74 Suppl 1(Suppl 1):S31-40. doi: 10.1212/WNL.0b013e3181c97ed3. Neurology. 2010. PMID: 20038761 Free PMC article. Review.
• Interferon-beta mechanisms of action in multiple sclerosis.

  Dhib-Jalbut S, Marks S. Dhib-Jalbut S, et al. Neurology. 2010 Jan 5;74 Suppl 1:S17-24. doi: 10.1212/WNL.0b013e3181c97d99. Neurology. 2010. PMID: 20038758
• Mechanisms of mitoxantrone in multiple sclerosis--what is known?

  Neuhaus O, Kieseier BC, Hartung HP. Neuhaus O, et al. J Neurol Sci. 2004 Aug 15;223(1):25-7. doi: 10.1016/j.jns.2004.04.015. J Neurol Sci. 2004. PMID: 15261556 Review.